News
CSL joins forces with Alentis on claudin candidate
CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.
News
Novartis taps China's Abogen for autoimmunity TCE
Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
R&D
Alzheimer’s: Starting the impossible journey
September was Alzheimer’s Month, and with that in mind pharmaphorum spoke to leaders at two biotechs about latest developments in the field.
News
New diabetes and obesity studies making waves at EASD
As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
News
Space pharma Varda raises $251m, and other financings
Varda has closed a $251m round to fuel its mission to make medicines in orbit, with TriGemX, Breye, AnaCardio, and ai3Bio also raising new funds.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
